User:Mr. Ibrahem/Daprodustat

Mr. Ibrahem/Daprodustat
Clinical data
Trade names	Duvroq, Jesduvroq
Other names	GSK1278863
AHFS/Drugs.com	Monograph
License data	US DailyMed: Daprodustat;
Routes of; administration	By mouth
Drug class	Hypoxia-inducible factor prolyl hydroxylase inhibitor
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid;
Chemical and physical data
Formula	C19H27N3O6
Molar mass	393.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CCCCC3n(c(=O)c1C(=O)NCC(=O)O)c(=O)n(c1O)C2CCCCC2;
	InChI InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,26H,1-11H2,(H,20,25)(H,23,24); Key:NVTKJBXOBFRPLQ-UHFFFAOYSA-N;

Daprodustat, sold under the brand name Duvroq among others, is a medication used to treat low red blood cells due to chronic kidney disease.^[1] It is used in those who have been on dialysis for more than four months.^[1] It is taken by mouth.^[1] It is used to reduce the need for blood transfusions.^[1]

Common side effects include high blood pressure, blood clots, and abdominal pain.^[1] Other side effects may include worsening heart failure and upper gastrointestinal bleeding.^[1] Use may increase the risk of death.^[1] It is not recommended in those with active cancer.^[1] It interacts with medications that affect CYP2C8.^[1] Use in pregnancy may harm the baby.^[1] It is a hypoxia-inducible factor prolyl hydroxylase inhibitor which works by increasing erythropoietin.^[1]^[2]

Daprodustat was approved for medical use in Japan in 2020,^[2] and the United States in 2023.^[1] It is the first by mouth treatment for low red blood cells caused by kidney disease.^[3]^[4] Previously injectable erythropoiesis-stimulating agents were used for this purpose.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r "Jesduvroq- daprodustat tablet, film coated". DailyMed. 1 February 2023. Archived from the original on 11 February 2023. Retrieved 11 February 2023.
^ ^a ^b Dhillon S (September 2020). "Daprodustat: First Approval". Drugs. 80 (14): 1491–1497. doi:10.1007/s40265-020-01384-y. PMC 7471535. PMID 32880805.
^ "FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis". U.S. Food and Drug Administration (FDA) (Press release). 1 February 2023. Archived from the original on 4 February 2023. Retrieved 3 February 2023. This article incorporates text from this source, which is in the public domain.
^ Harris, Emily (15 February 2023). "FDA Approves First Oral Treatment for Kidney Disease–Induced Anemia". Medical News in Brief. JAMA. 329 (9): 704. doi:10.1001/jama.2023.1556. PMID 36790833. Archived from the original on 19 March 2023. Retrieved 3 May 2023.
^ "Issue 4 - March 1, 2023". www.pbdrx.com. Archived from the original on 30 June 2023. Retrieved 14 May 2023.

[PI2023-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r "Jesduvroq- daprodustat tablet, film coated". DailyMed. 1 February 2023. Archived from the original on 11 February 2023. Retrieved 11 February 2023.

[Dh2020-2] Dhillon S (September 2020). "Daprodustat: First Approval". Drugs. 80 (14): 1491–1497. doi:10.1007/s40265-020-01384-y. PMC 7471535. PMID 32880805.

[FDA2023-3] "FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis". U.S. Food and Drug Administration (FDA) (Press release). 1 February 2023. Archived from the original on 4 February 2023. Retrieved 3 February 2023. This article incorporates text from this source, which is in the public domain.

[4] Harris, Emily (15 February 2023). "FDA Approves First Oral Treatment for Kidney Disease–Induced Anemia". Medical News in Brief. JAMA. 329 (9): 704. doi:10.1001/jama.2023.1556. PMID 36790833. Archived from the original on 19 March 2023. Retrieved 3 May 2023.

[5] "Issue 4 - March 1, 2023". www.pbdrx.com. Archived from the original on 30 June 2023. Retrieved 14 May 2023.

[1]

[2]

[3]

[4]

[5]